The 3R Principle: Advancing Clinical Application of Human Pluripotent Stem Cells

Overview

Journal Stem Cell Res Ther

Publisher Biomed Central

Date 2013 Mar 21

PMID 23510719

Citations 10

Authors

Michael D OConnor

Affiliations

Soon will be listed here.

Abstract

The first derivation of human embryonic stem cells brought with it a clear understanding that animal models of human disease might be replaced by an unlimited supply of human cells for research, drug discovery, and drug development. With the advent of clinical trials using human pluripotent stem cell-based therapies, it is both timely and relevant to reflect on factors that will facilitate future translation of this technology. Human pluripotent cells are increasingly being used to investigate the molecular mechanisms that underpin normal and pathological human development. Their differentiated progeny are also being used to identify novel pharmaceuticals, to screen for toxic effects of known chemicals, and to investigate cell or tissue transplantation strategies. The intrinsic assumption of these research efforts is that the information gained from these studies will be more accurate, and therefore of greater relevance, than traditional investigations based on animal models of human disease and injury. This review will therefore evaluate how animals and animal-derived products are used for human pluripotent stem cell research, and will indicate how efforts to further reduce or remove animals and animal products from this research will increase the clinical translation of human pluripotent stem cell technologies through drug discovery, toxicology screening, and cell replacement therapies.

Citing Articles

Facilitation of Tumor Stroma-Targeted Therapy: Model Difficulty and Co-Culture Organoid Method.

Feng Q, Shan X, Yau V, Cai Z, Xie S Pharmaceuticals (Basel). 2025; 18(1).

PMID: 39861125 PMC: 11769033. DOI: 10.3390/ph18010062.

Ion channel traffic jams: the significance of trafficking deficiency in long QT syndrome.

Mondejar-Parreno G, Moreno-Manuel A, Ruiz-Robles J, Jalife J Cell Discov. 2025; 11(1):3.

PMID: 39788950 PMC: 11717978. DOI: 10.1038/s41421-024-00738-0.

Replacing Animal Testing with Stem Cell-Organoids : Advantages and Limitations.

Park G, Rim Y, Sohn Y, Nam Y, Ju J Stem Cell Rev Rep. 2024; 20(6):1375-1386.

PMID: 38639829 PMC: 11319430. DOI: 10.1007/s12015-024-10723-5.

Clicker Training as an Applied Refinement Measure in Chickens.

Mahlis G, Kleine A, Luschow D, Bartel A, Wiegard M, Thoene-Reineke C Animals (Basel). 2023; 13(24).

PMID: 38136873 PMC: 10740453. DOI: 10.3390/ani13243836.

An integrated in vitro human iPSCs-derived neuron and in vivo animal approach for preclinical screening of anti-seizure compounds.

Zhao C, Rollo B, Shahid Javaid M, Huang Z, He W, Xu H J Adv Res. 2023; 64:249-262.

PMID: 37995945 PMC: 11464642. DOI: 10.1016/j.jare.2023.11.022.

References

Eastwood D, Findlay L, Poole S, Bird C, Wadhwa M, Moore M . Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4+ effector memory T-cells. Br J Pharmacol. 2010; 161(3):512-26. PMC: 2990151. DOI: 10.1111/j.1476-5381.2010.00922.x. View

Webb S . Burgeoning stem cell product market lures major suppliers. Nat Biotechnol. 2010; 28(6):535-6. DOI: 10.1038/nbt0610-535. View

Dolgin E . Putting stem cells to the test. Nat Med. 2010; 16(12):1354-7. DOI: 10.1038/nm1210-1354. View

Amore B, Gibbs J, Emery M . Application of in vivo animal models to characterize the pharmacokinetic and pharmacodynamic properties of drug candidates in discovery settings. Comb Chem High Throughput Screen. 2010; 13(2):207-18. DOI: 10.2174/138620710790596808. View

Kola I, Landis J . Can the pharmaceutical industry reduce attrition rates?. Nat Rev Drug Discov. 2004; 3(8):711-5. DOI: 10.1038/nrd1470. View

Paul S, Mytelka D, Dunwiddie C, Persinger C, Munos B, Lindborg S . How to improve R&D productivity: the pharmaceutical industry's grand challenge. Nat Rev Drug Discov. 2010; 9(3):203-14. DOI: 10.1038/nrd3078. View

Couture L . Scalable pluripotent stem cell culture. Nat Biotechnol. 2010; 28(6):562-3. DOI: 10.1038/nbt0610-562. View

Wall R, Shani M . Are animal models as good as we think?. Theriogenology. 2007; 69(1):2-9. DOI: 10.1016/j.theriogenology.2007.09.030. View

Sharma R, Greenhough S, Medine C, Hay D . Three-dimensional culture of human embryonic stem cell derived hepatic endoderm and its role in bioartificial liver construction. J Biomed Biotechnol. 2010; 2010:236147. PMC: 2821762. DOI: 10.1155/2010/236147. View

10.

Seiler A, Spielmann H . The validated embryonic stem cell test to predict embryotoxicity in vitro. Nat Protoc. 2011; 6(7):961-78. DOI: 10.1038/nprot.2011.348. View

11.

Muller F, Laurent L, Kostka D, Ulitsky I, Williams R, Lu C . Regulatory networks define phenotypic classes of human stem cell lines. Nature. 2008; 455(7211):401-5. PMC: 2637443. DOI: 10.1038/nature07213. View

12.

Ohmine S, Dietz A, Deeds M, Hartjes K, Miller D, Thatava T . Induced pluripotent stem cells from GMP-grade hematopoietic progenitor cells and mononuclear myeloid cells. Stem Cell Res Ther. 2011; 2(6):46. PMC: 3340555. DOI: 10.1186/scrt87. View

13.

Wobus A, Boheler K . Embryonic stem cells: prospects for developmental biology and cell therapy. Physiol Rev. 2005; 85(2):635-78. DOI: 10.1152/physrev.00054.2003. View

14.

OConnor M, Kardel M, Eaves C . Functional assays for human embryonic stem cell pluripotency. Methods Mol Biol. 2010; 690:67-80. DOI: 10.1007/978-1-60761-962-8_4. View

15.

Martin M, Muotri A, Gage F, Varki A . Human embryonic stem cells express an immunogenic nonhuman sialic acid. Nat Med. 2005; 11(2):228-32. DOI: 10.1038/nm1181. View

16.

Chambers S, Fasano C, Papapetrou E, Tomishima M, Sadelain M, Studer L . Highly efficient neural conversion of human ES and iPS cells by dual inhibition of SMAD signaling. Nat Biotechnol. 2009; 27(3):275-80. PMC: 2756723. DOI: 10.1038/nbt.1529. View

17.

OConnor M, McAvoy J . In vitro generation of functional lens-like structures with relevance to age-related nuclear cataract. Invest Ophthalmol Vis Sci. 2007; 48(3):1245-52. DOI: 10.1167/iovs.06-0949. View

18.

DAmour K, Bang A, Eliazer S, Kelly O, Agulnick A, Smart N . Production of pancreatic hormone-expressing endocrine cells from human embryonic stem cells. Nat Biotechnol. 2006; 24(11):1392-401. DOI: 10.1038/nbt1259. View

19.

Schwartz S, Hubschman J, Heilwell G, Franco-Cardenas V, Pan C, Ostrick R . Embryonic stem cell trials for macular degeneration: a preliminary report. Lancet. 2012; 379(9817):713-20. DOI: 10.1016/S0140-6736(12)60028-2. View

20.

Sullivan G, Bai Y, Fletcher J, Wilmut I . Induced pluripotent stem cells: epigenetic memories and practical implications. Mol Hum Reprod. 2010; 16(12):880-5. DOI: 10.1093/molehr/gaq091. View